Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 7/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.34 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014126 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL2014130 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL9073285 | 0.84 | GRIK1 (0.43) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL7168760 | 0.82 | GRIK1 (0.58) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL4556871 | 0.82 | GRIK1 (0.69) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL4556870 | 0.82 | GRIK1 (0.69) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL25466254 | 0.80 | GRIK1 (0.47) | GRIK1 | |
| SCHEMBL455204 | 0.78 | GRIK1 (0.42) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL3927257 | 0.78 | GRIK1 (0.55) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL7391128 | 0.77 | GRIK1 (0.37) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-6013792-A | INTERSTITIAL COLLAGENASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIOSTEOPOROSIS AGENTS | SYNTEX (U.S.A.), INC. (US) | 2000-01-11 | — | — | US | disclosed |
| CN-1044249-C | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5773428-A | BONE DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0807114-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0712403-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0726903-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-07-16 | — | — | EP | disclosed |
| CN-1134153-A | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1996-10-23 | — | — | CN | disclosed |
| WO-1996023791-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0712403-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004735-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-02-16 | — | — | WO | disclosed |
| US-4772325-A | CONTROLLED RELEASE, BORON TRIFLUORIDE COMPLEX WITH LEWIS BASE | KERR MANUFACTURING COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0079940-A4 | FLUORINE CONTAINING DENTAL MATERIALS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1985-07-01 | — | — | EP | disclosed |
| EP-0079940-A1 | FLUORINE CONTAINING DENTAL MATERIALS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-06-01 | — | — | EP | disclosed |
| WO-1982004259-A1 | FLUORINE CONTAINING DENTAL MATERIALS | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | GRIK1 2088/4885GRIK2 3792/4885GRIA2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.